We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rifampin may decrease the efficacy of crizotinib in lung cancer treatment.
- Authors
Chang, Ching‐Hsiung; Chang, Hsu‐Liang; Hsu, Jui‐Feng; Yang, Chih‐Jen
- Abstract
Crizotinib is an anticancer drug that acts as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, and it has been shown to have marked therapeutic efficacy in treating advanced nonsmall cell lung cancer harboring ALK rearrangement in clinical trials.[[1]] The median progression free survival (PFS) was 10.9 months, significantly longer than in chemotherapy group.[2] Crizotinib has been approved by the U.S. Food and Drug Administration (FDA) since 2011. Initial chest CT showed lung cancer with effusion (D; on Feb 28, 2018), and his lung cancer worsened with recurrence of accumulated effusion 2 months later (F; on June 12, 2018).
- Subjects
LUNG cancer; RIFAMPIN; NON-small-cell lung carcinoma; CANCER treatment
- Publication
Kaohsiung Journal of Medical Sciences, 2019, Vol 35, Issue 9, p580
- ISSN
1607-551X
- Publication type
Article
- DOI
10.1002/kjm2.12078